150 related articles for article (PubMed ID: 37403699)
1. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
[TBL] [Abstract][Full Text] [Related]
2. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
[TBL] [Abstract][Full Text] [Related]
3. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
Neville G; Marzario B; Shilling D; Hand CK; Heffron C
Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
[TBL] [Abstract][Full Text] [Related]
6. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
7. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract][Full Text] [Related]
8. Targeting
Phadke MS; Smalley KSM
J Clin Oncol; 2023 May; 41(14):2661-2664. PubMed ID: 36947724
[No Abstract] [Full Text] [Related]
9. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.
Murphy BM; Terrell EM; Chirasani VR; Weiss TJ; Lew RE; Holderbaum AM; Dhakal A; Posada V; Fort M; Bodnar MS; Carey LM; Chen M; Burd CJ; Coppola V; Morrison DK; Campbell SL; Burd CE
Nat Commun; 2022 Jun; 13(1):3153. PubMed ID: 35672316
[TBL] [Abstract][Full Text] [Related]
10. Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM; Osorio RC; Francois RA; Tawil ME; Tsai KK; Tetzlaff M; Daud A; Vasudevan HN
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611025
[TBL] [Abstract][Full Text] [Related]
11. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
Arak H; Erkiliç S; Yaslikaya Ş; Eylemer Mocan E; Aktaş G; Özdemir M; Semiz HS; Kiliçkap S; Özalp FR; Sever ÖN; Akdağ G; Ağaoğlu AB; Özçelik M; Sari M; Arcagök M; Anik H; Yayla ŞB; Sever N; Açar FP; Bayrakçi İ; Turhal S; Ayhan M; Kuş T;
J Immunother; 2024 Jun; 47(5):182-189. PubMed ID: 38333962
[TBL] [Abstract][Full Text] [Related]
12. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
Kodali N; Bhattaru A; Blanchard I; Sharma Y; Lipner SR
Melanoma Res; 2024 Mar; ():. PubMed ID: 38564430
[TBL] [Abstract][Full Text] [Related]
13. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract][Full Text] [Related]
14. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
15. The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
Geiger CE; Mrabet-Dahbi S; Berger I
Melanoma Res; 2024 Feb; 34(1):85-87. PubMed ID: 38127894
[No Abstract] [Full Text] [Related]
16. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract][Full Text] [Related]
18. Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract][Full Text] [Related]
19. Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
Bai X; Lawless AR; Czapla JA; Gerstberger SC; Park BC; Jung S; Johnson R; Yamazaki N; Ogata D; Umeda Y; Li C; Guo J; Flaherty KT; Nakamura Y; Namikawa K; Long GV; Menzies AM; Johnson DB; Sullivan RJ; Boland GM; Si L
JAAD Int; 2024 Jun; 15():105-114. PubMed ID: 38500872
[TBL] [Abstract][Full Text] [Related]
20.
Jenkins RW; Sullivan RJ
Melanoma Manag; 2016 Mar; 3(1):47-59. PubMed ID: 30190872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
